Ascendis Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021
Revenue	720.13	363.64	266.72	51.17	7.78
Revenue Growth (YoY)	98.03%	36.34%	421.20%	557.93%	11.87%
Cost of Revenue	94.92	44.26	44.4	12.14	3.52
Gross Profit	625.22	319.38	222.32	39.04	4.26
Selling, General & Admin	457.87	291.14	264.41	221.23	160.18
Research & Development	303.62	307	413.45	379.62	295.87
Operating Expenses	761.49	598.15	677.86	600.85	456.05
Operating Income	-136.27	-278.76	-455.54	-561.81	-451.79
Interest Expense	-80.65	-65.5	-44.07	-30.68	-3.91
Interest & Investment Income	15.3	14.36	16.86	7.43	0.69
Earnings From Equity Investments	16.31	-20.06	-18.4	-17.7	12.04
Currency Exchange Gain (Loss)	78.23	-27.15	12.35	40.43	59.03
Other Non Operating Income (Expenses)	-105.57	3.87	14.65	-15.48	-
Pretax Income	-212.65	-373.24	-474.14	-577.82	-383.94
Income Tax Expense	15.38	4.84	7.3	5.38	-0.37
Net Income	-228.03	-378.08	-481.45	-583.19	-383.58
Net Income to Common	-228.03	-378.08	-481.45	-583.19	-383.58
Shares Outstanding (Basic)	61	58	56	56	55
Shares Outstanding (Diluted)	61	58	56	56	55
Shares Change (YoY)	4.69%	2.85%	0.38%	2.37%	8.21%
EPS (Basic)	-3.76	-6.53	-8.55	-10.40	-7.00
EPS (Diluted)	-3.76	-6.53	-8.55	-10.40	-7.00
Free Cash Flow	45.41	-307.62	-469.8	-510.19	-441.35
Free Cash Flow Per Share	0.75	-5.31	-8.35	-9.10	-8.06
Gross Margin	86.82%	87.83%	83.36%	76.28%	54.71%
Operating Margin	-18.92%	-76.66%	-170.80%	-1097.85%	-5808.59%
Profit Margin	-31.67%	-103.97%	-180.51%	-1139.63%	-4931.56%
Free Cash Flow Margin	6.31%	-84.60%	-176.14%	-996.97%	-5674.38%
EBITDA	-131.42	-273.83	-437.11	-544.3	-436.85
EBITDA Margin	-18.25%	-75.30%	-163.89%	-	-
D&A For EBITDA	4.86	4.94	18.43	17.51	14.95
EBIT	-136.27	-278.76	-455.54	-561.81	-451.79
EBIT Margin	-18.92%	-76.66%	-170.80%	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q